Lv11
80 积分 2025-07-28 加入
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2天前
已完结
CKD progression, kidney failure, and mortality among US patients with IgA nephropathy
1个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1个月前
已完结
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
1个月前
已完结
Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip
1个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2个月前
已完结
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
2个月前
已完结
Natural History of Primary IgA Nephropathy
2个月前
已关闭
Further Evidence for the Mucosal Origin of Pathogenic IgA in IgA Nephropathy
2个月前
已完结
Dialysis for Chronic Kidney Failure
2个月前
已完结
皖公网安备34019202002308
